Droplet will share a brief overview of the LymphDetect™ technology and recent performance data; followed by a multidisciplinary physician panel discussing clinical use for assessing MRD using surgical drain fluid to guide initial adjuvant treatment for patients with HPV(-) Head and Neck cancer. The panel will include Ari Rosenberg, MD, James E. Bates, MD, and Kevin Contrera, MD, MPH. The technology will be introduced by Droplet’s own Chief Scientific Officer, Wendy Winckler, PhD, and the panel will be moderated by Droplet’s Chief Medical Officer, Haluk Tezcan, MD.

We will follow up with an invitation including additional details closer to the meeting.